Dear Sir:

When platelets are activated, they increase in size and change from a quiescent disc to a swollen sphere. Large platelets are more reactive and likely aggregate more than small ones \[[@b1-jos-2016-00409]\]. Mean platelet volume (MPV), an indicator of platelet size and activation, has been shown to predict ischemic stroke, myocardial infarction, and overall vascular mortality \[[@b2-jos-2016-00409],[@b3-jos-2016-00409]\]. The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVEIT) study showed that ezetimibe added to statin therapy further decreases low density lipoprotein cholesterol (LDL-C) levels and prevented acute coronary syndromes \[[@b4-jos-2016-00409]\]. In this study, we investigated the lowering effect of LDL-C and MPV changes in patients who are on statin-ezetimibe combination therapy and those who receive statin monotherapy.

Patients with acute ischemic cerebral infarctions (n=120) were divided into those who were on statin therapy (n=60) and those on statin plus ezetimibe (n=60). The statin group received either atorvastatin (20 mg; n=13) or rosuvastatin (10 mg; n=48). The statin plus ezetimibe group received ezetimibe (10 mg) on top of the same dose of statin (atorvastatin plus ezetimibe, n=14; rosuvastatin plus ezetimibe, n=47). Student's *t*-tests showed that MPV and serum LDL-C levels were more significantly decreased (MPV: *P*\<0.001; LDL-C: *P*=0.017) by statin plus ezetimibe combination therapy (MPV: from 7.39±1.04 \[5.8--9.2\] to 6.04±0.58 \[4.9--7.3\] fL; LDL-C: from 160.1±21.9 \[122-212\] to 79.5±22.9 \[33-158\] mg/dL) than statin monotherapy (MPV: from 7.47±0.74 \[5.6--11.6\] to 6.56±1.04 \[4.9--9.2\] fL; LDL-C: from 143.4±29.4 \[52--238\] to 95.6±21.7 \[41--150\] mg/dL). Total cholesterol and triglycerides, but not high-density lipoprotein-cholesterol, were more significantly altered with combination therapy than with statin monotherapy ([Table 1](#t1-jos-2016-00409){ref-type="table"}). A multivariate regression analysis showed that only LDL-C in the lipid profile correlated significantly with the MPV change. A Pearson correlation analysis showed a positive correlation between the post-treatment MPV and post-treatment LDL-C levels (*r*=0.230, *P*=0.012).

Statin has pleiotrophic effects and modulates platelet function by direct interactions with platelet membranes or by influencing signaling pathways, irrespective of the cholesterol-lowering effects. Aydin et al. reported that high doses of statin decrease MPV and LDL-C levels in patients with diabetes, but the changes in LDL-C and MPV did not correlate \[[@b5-jos-2016-00409]\]. Nevertheless, Marek et al. reported that MPV was correlated with small dense LDL-C \[[@b6-jos-2016-00409]\]. The possible mechanisms through which small dense LDL-C increases MPV include easier oxidation and glycation, which enhances the mobilization of arachidonic acid from phospholipids and decreases membrane fluidity. However, small dense-LDL-C measurements are time consuming and expensive in real life. In general, statin and ezetimibe induce reductions in all LDL-C subclasses. Ezetimibe blocks the critical mediator of cholesterol absorption, the Niemann-Pick C1-like 1 (NPC1L1) protein, on gastrointestinal tract epithelial cells as well as in hepatocytes, which causes them to absorb more LDL-C from the circulation and lower the circulating cholesterol level.

The previously proposed mechanisms of hypercholesterolemia in platelet activation are increased thromboxane A2 biosynthesis, inhibition of the platelet Na+/H+ antiport, decreased platelet endogenous nitric oxide production, and diminished endothelial nitric oxide synthase (eNOS) protein expression \[[@b7-jos-2016-00409]\]. In addition, platelet activation by high LDL-C through platelet signaling pathways has been reported \[[@b8-jos-2016-00409]\]. The effects of ezetimibe monotherapy on the LDL subclass profile are controversial. Kasper et al. reported that ezetimibe increases small dense LDL-C in healthy men \[[@b9-jos-2016-00409]\]. In contrast, other studies have reported that ezetimibe decreases all LDL-C subclasses, including small dense LDL-C \[[@b10-jos-2016-00409]\].

Our results showed that MPV and LDL-C levels were more significantly decreased by statin and ezetimibe combination therapy than statin monotherapy and that their levels are closely correlated. Our data suggest that the lowering of LDL-C may causally related with MPV changes and support the "Lower LDL-C, better outcome" findings of the IMPROVE-IT study \[[@b4-jos-2016-00409]\].
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###### 

Comparison of Lipid profile and mean platelet volume between statin and ezetimibe combination and statin monotherapy at baseline and post treatment

                  Statin plus ezetimibe   Stain only   *P*-value                                     
  --------------- ----------------------- ------------ ----------- ------------ ------------ ------- ----------
  TC (mg/dL)      234.5±36.8              165.3±19.7   -29.5       231.5±37.4   188.3±20.3   -19.6   0.039
  LDL-C (mg/dL)   160.1±21.9              79.5±22.9    -50.4       143.4±29.4   95.6±21.7    -33.4   0.017
  TG (mg/dL)      189.1±22.4              152.7±18.2   -19.2       183.5±21.9   163.7±13.6   -10.7   0.042
  HDL-C (md/dL)   35.2±3.5                44.7±1.9     21.2        39.4±2.5     47.8±5.8     17.6    0.474
  MPV (fL)        7.39±1.04               6.04±0.58    -18.3       7.47±0.74    6.56±1.04    -12.2   \< 0.001

TC, Total cholesterol; LDL-C, Low density lipoprotein cholesterol; TG, Triglyceride; HDL-C, High density lipoprotein cholesterol; MPV, Mean platelet volume.
